PropertyValue
?:abstract
  • BACKGROUND: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that emerged late in 2019 causing COVID-19 (coronavirus disease-2019) may adversely affect the cardiovascular system. Publications from Asia, Europe and North America have identified cardiac troponin as an important prognostic indicator for patients hospitalized with COVID-19. We recognized from publications within the first 6 months of the pandemic that there has been much uncertainty on the reporting, interpretation, and pathophysiology of an increased cardiac troponin concentration in this setting. CONTENT: The purpose of this mini-review is: a) to review the pathophysiology of SARS-CoV-2 and the cardiovascular system, b) to overview the strengths and weaknesses of selected studies evaluating cardiac troponin in patients with COVID-19, and c) recommend testing strategies in the acute period, in the convalescence period and in long-term care for patients who have become ill with COVID-19. SUMMARY: This review provides important educational information and identifies gaps in understanding the role of cardiac troponin and COVID-19. Future, properly designed studies will hopefully provide the much-needed evidence on the path forward in testing cardiac troponin in patients with COVID-19.
?:creator
?:doi
?:doi
  • 10.1093/clinchem/hvaa225
?:journal
  • Clin_Chem
?:license
  • no-cc
?:pdf_json_files
  • document_parses/pdf_json/bcf48ca8af94ffedb8b82144a4d4c49fa7011751.json
?:pmcid
?:pmid
?:pmid
  • 33045044.0
?:publication_isRelatedTo_Disease
?:sha_id
?:source
  • Medline; PMC
?:title
  • Cardiac Troponin Testing in Patients with COVID-19: A Strategy for Testing and Reporting Results
?:type
?:year
  • 2020-10-12

Metadata

Anon_0  
expand all